Database | Recombinant Antibodies And Mimetics Database

What can we help you find?

You are searching for:

Category A

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category B

Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation

Category C

Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category D

Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation

Category E

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Category F

Original source/host: Animal
Discovery method: immunisation-based selection post 2020
Production: Recombinant expression with animal-derived biomaterials used in production or final formulation

Category G

Original source/host: Unknown
Discovery method: Unknown
Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation

Uncategorised Antibodies

Uncategorised Antibodies have Antibody/Binder Origins set in such a way as to prevent them from being assigned to a valid Antibody Category.

Click here to view all Antibody Category descriptions and to search directly by Antibody Category

Category A
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category B
- Original source/host: Animal (historic hybridoma) OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
- Recombinantly reformatted hybridomas are included as they align with the May 2020 EURL ECVAM recommendation, which permits continued use of existing, sequenced, and well-characterised hybridomas to produce recombinant monoclonal antibodies in vitro, as animals are no longer directly involved
- Naïve, non-immunised animal B cell-derived in vitro antibody display libraries align with the May 2020 EURL ECVAM recommendation to no longer authorise the development and production of antibodies through animal immunisation
Search
Category C
- Original source/host: Naïve (human-derived B cell) or synthetic, natural or consensus framework (any species, published framework sequences) antibody or mimetic
- Discovery method: Non-immunisation based in vitro display selection of antibody or mimetic
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category D
- Original source/host: Animal OR naïve, non-immunised animal B cell-derived in vitro antibody display library
- Discovery method: immunisation pre-2020 OR in vitro display selection of antibodies
- Production: Recombinant expression ; animal-derived biomaterials used in production or final formulation
Search
Category E
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search
Category F
- Original source/host: Animal
- Discovery method: immunisation-based selection post 2020
- Production: Recombinant expression with animal-derived biomaterials used in production or final formulation
Search
Category G
- Original source/host: Unknown
- Discovery method: Unknown
- Production: Recombinant expression with no use of animal-derived biomaterials in production or final formulation
Search

3561-3570 of 4090 results

Catalogue Number:

PX-TA1867

Category:

Nadunolimab Biosimilar – Anti-IL1RAP mAb – Research Grade

Target:	IL1RAP
Target Alias Name:	Nadunolimab//IL1RAP/anti-IL1RAP
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1 Kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1259

Category:

Namilumab Biosimilar – Anti-CSF2/ GM-CSF mAb – Research Grade

Target:	CSF2/ GM-CSF
Target Alias Name:	Namilumab/MT203/CSF2/ GM-CSF/anti-CSF2/ GM-CSF
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1868

Category:

Naptumomab Biosimilar – Anti-TPBG mAb – Research Grade

Target:	TPBG
Target Alias Name:	Naptumomab//TPBG/anti-TPBG
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1 Kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1050

Category:

Naptumomab Estafenatox Biosimilar – Anti-TPBG mAb – Research Grade

Target:	TPBG
Target Alias Name:	Naptumomab Estafenatox/ABR-217620/ANYARA/TTS CD3/TPBG/anti-TPBG
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	Fab-G1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1419

Category:

Naratuximab Biosimilar – Anti-CD37/ TSPAN26 mAb – Research Grade

Target:	CD37/ TSPAN26
Target Alias Name:	Naratuximab/K7153A/CD37/ TSPAN26/anti-CD37/ TSPAN26
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA2079

Category:

Narlumosbart Biosimilar – Anti-ODF mAb – Research Grade

Target:	ODF
Target Alias Name:	anti-ODF/ TNF-related activation-induced cytokine/ Osteoclast differentiation factor/ TNFSF11/ TRANCE/ Osteoprotegerin ligand/ RANKL/ Tumor necrosis factor ligand superfamily member 11/ Receptor activator of nuclear factor kappa-B ligand/ CD254/ OPGL
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1271

Category:

Narnatumab Biosimilar – Anti-MST1R/ CD136 mAb – Research Grade

Target:	MST1R/ CD136
Target Alias Name:	Narnatumab/IMC RON-8/RON8/MST1R/ CD136/anti-MST1R/ CD136
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG1-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1495

Category:

Narsoplimab Biosimilar – Anti-MASP2 mAb – Research Grade

Target:	MASP2
Target Alias Name:	Narsoplimab /OMS721/MASP2/anti-MASP2
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-lambda
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1053

Category:

Natalizumab Biosimilar – Anti-ITGA4/ CD49d mAb – Research Grade

Target:	ITGA4/ CD49d
Target Alias Name:	Natalizumab/AN 100226/BG00002/ITGA4/ CD49d/anti-ITGA4/ CD49d
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG4-kappa
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Catalogue Number:

PX-TA1026

Category:

Navicixizumab Biosimilar – Anti-DLL4 mAb – Research Grade

Target:	DLL4
Target Alias Name:	Navicixizumab/Navicixizumab/DLL4/anti-DLL4
Species Reactivity:	Human
Type:	Primary Recombinant
Isotype/Mimetic:	IgG2Kappa (bispecific)
Host Species:	Human
Animal-Derived Biomaterials Used:	None
Sequence Available	No
Original Discovery Method	Unknown
Original Discovery Information Provided On Datasheet	No
Antibody/Binder Origins:	Unknown discovery source/method, In vitro recombinant expression

Viewing 3561-3570 of 4090 results

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.